You Position: Home > Paper

Liver injury caused by antiviral agents for COVID-19

( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
2
DOI:
10.3760/cma.j.issn.1674-2397.2020.02.004
Key Word:
新型冠状病毒;新型冠状病毒肺炎;抗病毒药物;肝损害;2019-nCoV;COVID-19;Antiviral agents;Liver damage

Abstract: Antiviral therapy is important for COVID-19. Currently, the anti-2019-nCoV drugs in clinical trials include broad-spectrum antiviral drugs (alpha interferon and ribavirin), hemagglutinin inhibitors (arbidol), human immunodeficiency virus protease inhibitors (lopinavir/ritonavir and darunavir/cobicistat), nucleoside analogues (favipiravir and remdesivir) and antimalarial drug (chloroquine); while liver damage may occur in some patients with the medication. This article reviews the research on liver damage associated with anti-2019-nCoV drugs, aiming at promoting the safe and effective antiviral therapy for COVID-19 patients.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn